Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels.

Abstract

BACKGROUND:

We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (Seq-BNCT) in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48 hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization.

MATERIAL AND METHODS:

Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization, followed by Seq-BNCT (Th+ Seq-BNCT) or Seq-Beam Only (Th+ Seq-BO) in the window of normalization. Boron microdistribution was assessed by neutron autoradiography.

RESULTS:

Th+ Seq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between tumors pre-treated and not pre-treated with thalidomide were observed.

CONCLUSION:

Th+ Seq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in tumor boron microdistribution is associated to an improvement in tumor control.

• Authors: Ana J Molinari, Silvia I Thorp, Agustina M Portu, Gisela Saint Martin, Emiliano C C Pozzi, Elisa M Heber, Silva Bortolussi, Maria E Itoiz, Romina F Aromando, Andrea Monti Hughes, Marcela A Garabalino, Saverio Altieri, Verónica A Trivillin, Amanda E Schwint
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 54 Issue 1 Pg. 99-106 (Jan 2015) ISSN: 1651-226X [Electronic] England
• PMID: 24960584 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Boron Compounds
• Carcinogens
• decahydrodecaborate
• Phenylalanine
• Thalidomide
• 9,10-Dimethyl-1,2-benzanthracene

Topics

• 9,10-Dimethyl-1,2-benzanthracene
• Angiogenesis Inhibitors (therapeutic use)
• Animals
• Boron Compounds (pharmacokinetics, therapeutic use)
• Boron Neutron Capture Therapy (methods)
• Carcinogens
• Cricetinae
• Mesocricetus
• Mouth Neoplasms (blood supply, chemically induced, metabolism, radiotherapy)
• Neovascularization, Pathologic (drug therapy)
• Phenylalanine (analogs & derivatives, pharmacokinetics, therapeutic use)
• Precancerous Conditions (blood supply, chemically induced, metabolism, radiotherapy)
• Thalidomide (therapeutic use)